Advaxis seeks FDA approval to begin first-in-human trial of ADXS-HER2
The trial is scheduled to start in the first quarter of 2015. It is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
These high-risk patients typically do not respond well to standard therapies. These results were published in The Lancet Oncology. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and
The two parties have also entered into an exclusive license agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration. Bristol-Myers Squibb